Performance of the accelerated assessment of the European Medicines Agency
A minority of medicinal products are assessed under the accelerated pathway. HTA bodies also assess these products more quickly, but do not always perceive an important clinical advantage over alternatives.
Authors
- Enrico Costa (ORCID: https://orcid.org/0000-0003-2616-994X)
- Armando A. Genazzani (ORCID: https://orcid.org/0000-0003-1923-7430)
- Valentina Boscaro (ORCID: https://orcid.org/0000-0002-3344-8624)
- Gianluca Miglio (ORCID: https://orcid.org/0000-0002-6602-2099)
- Vittorio Del Grosso
- Giorgio Casilli (ORCID: https://orcid.org/0000-0001-5181-5099)
- M. Perini
Institutions
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Utrecht University (NL)
- Italian Medicines Agency (IT)
- Pharmo Institute (NL)
- University of Turin (IT)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1111/bcp.16385
- Citations
- 3
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 9.39
Funders
- Ministero della Salute